Experimental study of carvedilol in preventing the transition from subclinical portal hypertension to clinical portal hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026206

Enrollment

Unknown

Registered

2019-09-26

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

portal hypertension

Interventions

A:Carvedilol

B:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 80 years; 2. Cirrhosis diagnosed by biopsy or imaging, ultrasound and instantaneous elastic imaging of liver; 3. Subclinical portal hypertension; 4. HVPG from 5 to 10.

Exclusion criteria

Exclusion criteria: 1. Decompensated events (bleeding, ascitic fluid, history of liver and brain, liver cancer); 2. Esophageal and gastric fundus varicose veins; 3. Liver and kidney insufficiency; 4. Venous thrombus; 5. Patients with baseline bilirubin > 3 mg/dL, or platelet 2.7, renal failure (creatinine > 2mg/dL), life expectancy less than 12 months, patients with ß blocker allergy or taboo use, anticoagulant therapy, antihepatitis C therapy, pregnancy, lactation.

Design outcomes

Primary

Measure	Time frame
HVPG;	—

Secondary

Measure	Time frame
liver stiffness;esophageal and gastric varices;heart rate;	—

Countries

China

Contacts

Public ContactZhang Chunqing

Shandong Provincial Hospital

13583188661@126.com+86 15168886028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026